Novel Risk Tool IDs Those at Risk for Contrast-Associated Acute Kidney Injury

WEDNESDAY, March 29, 2023 (HealthDay News) -- A novel risk assessment tool can be used preoperatively to identify patients at risk for contrast-associated acute kidney injury (CA-AKI) after elective endovascular abdominal aortic aneurysm repair (EVAR), according to a study published online Feb. 28 in the Annals of Vascular Surgery.
Drew J. Braet, M.D., from the University of Michigan in Ann Arbor, and colleagues developed and validated a preprocedure CA-AKI risk stratification tool for elective EVAR patients. The derivation cohort included 7,043 patients, while the validation cohort included 62,986.
The researchers found that age (odds ratio [OR], 1.021), female sex (OR, 1.393), glomerular filtration rate (GFR) <30 mL/min (OR, 5.068), current smoking (OR, 1.942), chronic obstructive pulmonary disease (OR, 1.402), maximum abdominal aortic aneurysm (AAA) diameter (OR, 1.018), and presence of iliac artery aneurysm (OR, 1.352) were associated with increased odds of CA-AKI. The risk prediction calculator demonstrated a higher risk for CA-AKI after EVAR for patients with a GFR <30 mL/min, women, and patients with a maximum AAA diameter of >6.9 cm. Similarly, the validation cohort showed that GFR <30 mL/min (OR, 4.668), female sex (OR, 1.352), and maximum AAA diameter >6.9 cm (OR, 1.824) were associated with an increased risk for CA-AKI after EVAR.
“Prospective studies are needed to determine the efficacy of our model,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Related Posts
New Biden Plan Would Help Pregnant Women Fight Opioid Addiction
FRIDAY, Oct. 21, 2022 (HealthDay News) -- A new plan from the Biden...
Midday Naps & Health: How Long You Nap May Be Key
THURSDAY, April 27, 2023 (HealthDay News) -- If you're longing for a nap, try to...
Merck pedirá a la FDA la aprobación de emergencia de su nueva pastilla antiviral contra la COVID
VIERNES, 1 de octubre de 2021 (HealthDay News) -- La gigante farmacéutica Merck...
¿Es la berberina de verdad el ‘Ozempic natural’? Unos expertos sopesan ventajas y desventajas
VIERNES, 16 de junio de 2023 (HealthDay News) -- La berberina, un complemento...
